Palvella Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Palvella Therapeutics, Inc. (PVLA) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 56.30 million shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-05-17
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 56.30M shares, a 1.97% increase year-over-year.
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 56.00M shares, a 5.48% increase year-over-year.
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 54.34M shares, a 10.10% increase year-over-year.
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 52.37M shares, a 6.44% increase year-over-year.
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 54.48M shares, a 7.62% increase from fiscal 2019.
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 50.63M shares, a 4.63% decline from fiscal 2018.
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 53.08M shares, a 20.83% increase from fiscal 2017.
- Palvella Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2017 was 43.93M shares, a 5.32% increase from fiscal 2016.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 16 month |
|---|---|---|---|---|---|---|---|---|---|
| 2021-03-31 | 56.30M shares 10-Q · filed 2021-05-17 | 56.15M shares derived: average of 2 quarters · filed 2021-05-17 | 55.54M shares derived: average of 3 quarters · filed 2021-05-17 | 54.75M shares derived: average of 4 quarters · filed 2021-05-17 | |||||
| 2020-12-31 | 56.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | 55.17M shares derived: average of 2 quarters · filed 2021-03-31 | 54.24M shares derived: average of 3 quarters · filed 2021-03-31 | 54.48M shares 10-K · filed 2021-03-31 | |||||
| 2020-09-30 | 54.34M shares 10-Q · filed 2020-11-04 | 53.36M shares derived: average of 2 quarters · filed 2020-11-04 | 53.98M shares 10-Q · filed 2020-11-04 | 53.75M shares derived: average of 4 quarters · filed 2021-05-17 | |||||
| 2020-06-30 | 52.37M shares 10-Q · filed 2020-08-10 | 53.79M shares 10-Q · filed 2020-08-10 | 53.56M shares derived: average of 3 quarters · filed 2021-05-17 | 52.51M shares derived: average of 4 quarters · filed 2021-05-17 | |||||
| 2020-03-31 | 55.21M shares 10-Q · filed 2021-05-17 | 54.15M shares derived: average of 2 quarters · filed 2021-05-17 | 52.55M shares derived: average of 3 quarters · filed 2021-05-17 | 51.71M shares derived: average of 4 quarters · filed 2021-05-17 | |||||
| 2019-12-31 | 53.09M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | 51.22M shares derived: average of 2 quarters · filed 2021-03-31 | 50.55M shares derived: average of 3 quarters · filed 2021-03-31 | 50.63M shares 10-K · filed 2021-03-31 | |||||
| 2019-09-30 | 49.35M shares 10-Q · filed 2020-11-04 | 49.28M shares derived: average of 2 quarters · filed 2020-11-04 | 49.80M shares 10-Q · filed 2020-11-04 | 50.90M shares derived: average of 4 quarters · filed 2020-11-04 | |||||
| 2019-06-30 | 49.20M shares 10-Q · filed 2020-08-10 | 50.03M shares 10-Q · filed 2020-08-10 | 51.41M shares derived: average of 3 quarters · filed 2020-08-10 | 52.08M shares derived: average of 4 quarters · filed 2020-08-10 | |||||
| 2019-03-31 | 50.87M shares 10-Q · filed 2020-05-11 | 52.52M shares derived: average of 2 quarters · filed 2020-05-11 | 53.04M shares derived: average of 3 quarters · filed 2020-05-11 | 53.28M shares derived: average of 4 quarters · filed 2020-05-11 | |||||
| 2018-12-31 | 54.16M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | 54.13M shares derived: average of 2 quarters · filed 2020-03-13 | 54.08M shares derived: average of 3 quarters · filed 2020-03-13 | 53.08M shares 10-K · filed 2020-03-13 | |||||
| 2018-09-30 | 54.09M shares 10-Q · filed 2019-11-12 | 54.04M shares derived: average of 2 quarters · filed 2019-11-12 | 52.72M shares 10-Q · filed 2019-11-12 | 50.74M shares derived: average of 4 quarters · filed 2019-11-12 | |||||
| 2018-06-30 | 53.98M shares 10-Q · filed 2019-08-09 | 52.02M shares 10-Q · filed 2019-08-09 | 49.63M shares derived: average of 3 quarters · filed 2019-08-09 | 48.32M shares derived: average of 4 quarters · filed 2019-08-09 | |||||
| 2018-03-31 | 50.05M shares 10-Q · filed 2019-05-10 | 47.45M shares derived: average of 2 quarters · filed 2019-05-10 | 46.43M shares derived: average of 3 quarters · filed 2019-05-10 | 45.67M shares derived: average of 4 quarters · filed 2019-05-10 | |||||
| 2017-12-31 | 44.85M shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | 44.62M shares derived: average of 2 quarters · filed 2019-03-18 | 44.22M shares derived: average of 3 quarters · filed 2019-03-18 | 43.93M shares 10-K · filed 2019-03-18 | |||||
| 2017-09-30 | 44.39M shares 10-Q · filed 2018-11-07 | 44.39M shares 10-Q · filed 2017-11-13 | 43.90M shares derived: average of 2 quarters · filed 2018-11-07 | 43.62M shares 10-Q · filed 2018-11-07 | 43.62M shares 10-Q · filed 2017-11-13 | 43.48M shares derived: average of 4 quarters · filed 2018-11-07 | |||
| 2017-06-30 | 43.41M shares 10-Q · filed 2018-08-09 | 43.41M shares 10-Q · filed 2017-08-11 | 43.24M shares 10-Q · filed 2018-08-09 | 43.24M shares 10-Q · filed 2017-08-11 | 43.18M shares derived: average of 3 quarters · filed 2018-08-09 | 43.15M shares derived: average of 4 quarters · filed 2018-08-09 | |||
| 2017-03-31 | 43.06M shares 10-Q · filed 2018-05-10 | 43.06M shares 10-Q · filed 2017-05-15 | 43.07M shares derived: average of 2 quarters · filed 2018-05-10 | 43.07M shares derived: average of 3 quarters · filed 2018-05-10 | 42.52M shares derived: average of 4 quarters · filed 2018-05-10 | ||||
| 2016-12-31 | 43.07M shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | 43.07M shares derived: average of 2 quarters · filed 2018-03-15 | 42.33M shares derived: average of 3 quarters · filed 2018-03-15 | 41.71M shares 10-K · filed 2018-03-15 | 41.71M shares 10-K · filed 2017-03-30 | ||||
| 2016-09-30 | 43.06M shares 10-Q · filed 2017-11-13 | 41.96M shares derived: average of 2 quarters · filed 2017-11-13 | 41.26M shares 10-Q · filed 2017-11-13 | 40.89M shares derived: average of 4 quarters · filed 2017-11-13 | |||||
| 2016-06-30 | 40.86M shares 10-Q · filed 2017-08-11 | 40.35M shares 10-Q · filed 2017-08-11 | 40.17M shares derived: average of 3 quarters · filed 2017-08-11 | 39.85M shares derived: average of 4 quarters · filed 2017-08-11 | |||||
| 2016-03-31 | 39.83M shares 10-Q · filed 2017-05-15 | 39.83M shares derived: average of 2 quarters · filed 2017-05-15 | 39.51M shares derived: average of 3 quarters · filed 2017-05-15 | 36.99M shares derived: average of 4 quarters · filed 2017-05-15 | |||||
| 2015-12-31 | 39.82M shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | 39.35M shares derived: average of 2 quarters · filed 2017-03-30 | 36.05M shares derived: average of 3 quarters · filed 2017-03-30 | 34.39M shares 10-K · filed 2017-03-30 | |||||
| 2015-09-30 | 38.89M shares 10-Q · filed 2016-11-10 | 34.16M shares derived: average of 2 quarters · filed 2016-11-10 | 32.58M shares 10-Q · filed 2016-11-10 | 29.40M shares derived: average of 4 quarters · filed 2016-11-10 | |||||
| 2015-06-30 | 29.43M shares 10-Q · filed 2016-08-11 | 29.36M shares 10-Q · filed 2016-08-11 | 26.24M shares derived: average of 3 quarters · filed 2016-08-11 | 22.64M shares derived: average of 4 quarters · filed 2016-08-11 | |||||
| 2015-03-31 | 29.29M shares 10-Q · filed 2016-05-12 | 24.65M shares derived: average of 2 quarters · filed 2016-05-12 | 20.37M shares derived: average of 3 quarters · filed 2016-05-12 | 18.24M shares derived: average of 4 quarters · filed 2016-05-12 | |||||
| 2014-12-31 | 20.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | 15.92M shares derived: average of 2 quarters · filed 2016-03-23 | 14.55M shares derived: average of 3 quarters · filed 2016-03-23 | 13.87M shares 10-K · filed 2016-03-23 | |||||
| 2014-09-30 | 11.83M shares 10-Q · filed 2015-11-13 | 11.83M shares derived: average of 2 quarters · filed 2015-11-13 | 11.83M shares 10-Q · filed 2015-11-13 | 5.00M shares 10-Q · filed 2014-12-12 | |||||
| 2014-06-30 | 11.83M shares 10-Q · filed 2015-08-13 | 11.83M shares 10-Q · filed 2015-08-13 | |||||||
| 2014-03-31 | 11.83M shares 10-Q · filed 2015-05-14 | ||||||||
| 2013-12-31 | 11.83M shares 10-K · filed 2015-03-30 | ||||||||
| 2013-09-30 | 6.10M shares 10-Q · filed 2014-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |